ArticleOncogene1999
Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes.
Article in Oncogene, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 115 citations in OpenAlex.
- ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602).Clinical cancer research : an official journal of the American Association for Cancer Research · 2013Trial
- FGF2 Stimulates the Growth and Improves the Melanocytic Commitment of Trunk Neural Crest Cells.Cellular and molecular neurobiology · 2020Article
- Upregulation of Fibroblast Growth Factors Caused by Heart and Neural Crest Derivatives Expressed 2 Suppression in Endometriotic Cells: A Possible Therapeutic Target in Endometriosis.Reproductive sciences (Thousand Oaks, Calif.) · 2019Article
- Review
- FGF5 is expressed in melanoma and enhances malignancyOncotarget · 2017Article
- The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review.Journal of immunology research · 2016Review
- Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations.Pathology oncology research : POR · 2015Article
- The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.Pigment cell & melanoma research · 2015Article
- Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer.Virchows Archiv : an international journal of pathology · 2014Article
- A novel FGF2 antagonist peptide P8 with potent antiproliferation activity.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- Identification of a novel peptide that blocks basic fibroblast growth factor-mediated cell proliferation.Oncotarget · 2013Article
- Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis.Cancer biology & therapy · 2013Article
- Recombinant adeno-associated virus serotype 6 efficiently transduces primary human melanocytes.PloS one · 2013Article
- A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours.British journal of cancer · 2012Article
- Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.The Journal of investigative dermatology · 2011Article
- Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R.Melanoma research · 2011Article
- The crosstalk of RAS with the TGF-β family during carcinoma progression and its implications for targeted cancer therapy.Current cancer drug targets · 2010Review
- Placental gene transfer: transgene screening in mice for trophic effects on the placenta.American journal of obstetrics and gynecology · 2009Article
- Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma.Molecular cancer research : MCR · 2009Article
- Melanoma and the tumor microenvironment.Current oncology reports · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Basic fibroblast growth factor (bFGF or FGF-2) is produced by nearly all melanomas in vitro and in vivo but not by normal melanocytes, which require exogenous bFGF for growth. In this study, we transduced normal human melanocytes to overexpress two forms of bFGF: (bFGF-Long and bFGF-Short) using replication-deficient adenovirus 5 vectors. bFGF-Long induced the 17.8, 22.5, 23.1 and 24.2 kDa forms of bFGF, whereas bFGF-Short induced only the 17.8 kDa mature form. Growth of cultured melanocytes transduced with either vector was similar to that of nevus and melanoma cells and was independent of exogenous bFGF and of insulin/insulin-like growth factor 1, and cyclic AMP enhancers, requiring only phorbol ester as an exogenous mitogen. Like primary melanoma cells, transduced normal melanocytes grew anchorage independently in soft agar. When injected into the dermis of human skin grafted to mice, bFGF-transduced melanocytes proliferated for at least 20 days, whereas cells from control cultures showed poor survival and no proliferation. These results demonstrate that bFGF upregulation is a critical component in melanoma progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.